Brentuximab vedotin (solution)
Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab , and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].
Product Specifications
CAS Number
914088-09-8
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brentuximab-vedotin-solution.html
Purity
99.73
Solubility
10 mM in DMSO
Smiles
[Brentuximabvedotin(solution)]
Molecular Weight
153000 (average)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
P27 / KIP1 (SX53G8), CF647 conjugate, 0.1mg/mL
CD106 / VCAM1 (1.4C3), CF594 conjugate, 0.1mg/mL
Calretinin / Calbindin 2 (Mesothelioma Marker) (CALB2/2603), CF594 conjugate, 0.1mg/mL
